RxDoctor Payments Data

Krupa Patel

Foot & Ankle Surgery · Morris Plains, NJNPI 1013240357

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $236,606 of the $281,196 with a category attached, or 84.1%. Stryker accounts for 98.6% of it on its own, with 32 other manufacturers making up the rest. Among foot & ankle surgery clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$281,196in general payments, 2019–2025

Across 453 payments — averaging $620.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$277K
  • Novus Surgical Solutions LLC$1K
  • Averitas Pharma Inc.$645
  • Organogenesis Inc.$257
  • Kerecis Limited$225
  • GRT US Holding, Inc.$159
  • plus $1K from 27 others

What the payments were for

  • Consulting fees$236,60684%
  • Travel & lodging$31,00611%
  • Food & beverage$12,3844%
  • Education$1,2000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$281,196 in reported general payments places this provider in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.

See all foot & ankle surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$130,305
Medicare patients
270
Services billed
4,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$13,925
Ciclopirox15$596
Methylprednisolone18$146
Doxycycline Hyclate17$80
Naproxen33$71
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$63
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$90$13,92511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.

Other foot & ankle surgery in Morris Plains

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →